CD47 and neoplasm: Results showed that the combination of GenSci059 with rituximab significantly inhibited Raji model tumor growth, with a TGI of 94.6% compared to 55.1% for GenSci059 monotherapy and 8.0% for rituximab monotherapy (Fig. 5D), indicating that GenSci059 can be combined with antibodies against other tumor antigens to broaden the application of anti-CD47 cancer immunotherapy.